Form 4: Dianthus Therapeutics CFO & CBO Ryan Savitz Granted Stock Options

Ryan Savitz, CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options to purchase 150,000 shares of common stock on February 3, 2025.

Summary

• On February 3, 2025, Ryan Savitz, the CFO & CBO of Dianthus Therapeutics, Inc., was granted stock options.
• These options allow him to purchase 150,000 shares of Dianthus Therapeutics' common stock at an exercise price of $22.07 per share.
• The stock options vest in equal monthly installments over four years, starting January 1, 2025, contingent upon Savitz's continued service to the company.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance and the executive's role in it.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing long-term value creation.
• The vesting schedule encourages continued service and commitment from the CFO & CBO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Granting stock options to executives is a common practice in the biotechnology industry to attract and retain talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Comparable companies like Amgen, Regeneron, and Biogen also utilize stock options to incentivize their executives.
• The vesting schedule of four years with monthly installments is a typical arrangement to ensure long-term commitment.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the executive to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates